STOCK TITAN

Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation by CEO Kimberly Blackwell and CFO Melissa Epperly in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 a.m. ET. This event will be available via live webcast on the company’s website, with an archived version to follow. Zentalis is a clinical-stage biopharmaceutical company focusing on oncology therapeutics, developing candidates targeting pivotal cancer pathways, including ZN-c3 and ZN-d5. For more details, visit www.zentalis.com.

Positive
  • None.
Negative
  • None.

NEW YORK and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, and Melissa Epperly, MBA, Chief Financial Officer of Zentalis, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:30 a.m. ET.

A live webcast will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.

About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the United States and globally and our participation in upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidates; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; the COVID-19 pandemic has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Investor Contact:

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact:

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com


FAQ

What is the purpose of Zentalis Pharmaceuticals' participation in the Jefferies Healthcare Conference on June 9, 2022?

Zentalis Pharmaceuticals is participating to discuss its strategies and developments in oncology therapeutics, featuring insights from CEO Kimberly Blackwell and CFO Melissa Epperly.

How can I access the webcast of Zentalis Pharmaceuticals' fireside chat at the Jefferies Healthcare Conference?

The webcast can be accessed live through the Investors section of Zentalis Pharmaceuticals' website and will be archived afterwards.

What products is Zentalis Pharmaceuticals developing?

Zentalis is developing several oncology candidates, including ZN-c3, a Wee1 inhibitor, and ZN-d5, a BCL-2 inhibitor, targeting advanced solid tumors and hematologic malignancies.

Where is Zentalis Pharmaceuticals headquartered?

Zentalis Pharmaceuticals operates in New York and San Diego.

What stock symbol represents Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals is listed under the stock symbol ZNTL on Nasdaq.

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

ZNTL Rankings

ZNTL Latest News

ZNTL Stock Data

217.36M
64.53M
3.83%
98.06%
6.97%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO